Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has earned an average recommendation of “Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $65.44.

Several analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective on the stock. Guggenheim raised their price objective on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. Wolfe Research initiated coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective for the company. JPMorgan Chase & Co. lifted their price target on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Finally, Wells Fargo & Company initiated coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective for the company.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00. Following the sale, the chief executive officer now owns 85,942 shares of the company’s stock, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 52,500 shares of company stock worth $2,305,625 over the last three months. Corporate insiders own 21.70% of the company’s stock.

Institutional Trading of Vera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Huntington National Bank bought a new stake in shares of Vera Therapeutics during the fourth quarter worth $26,000. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics during the fourth quarter worth $34,000. GF Fund Management CO. LTD. bought a new stake in shares of Vera Therapeutics in the fourth quarter worth $56,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after purchasing an additional 350 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after purchasing an additional 1,387 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

VERA stock opened at $29.52 on Friday. The business’s fifty day moving average is $37.82 and its 200-day moving average is $40.72. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.87 billion, a P/E ratio of -11.31 and a beta of 1.11. Vera Therapeutics has a twelve month low of $25.99 and a twelve month high of $51.61.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.